OSI Pharmaceuticals to close Boulder office - Denver Business Journal:

sucujovide.wordpress.com
Melville, N.Y.-based OSI (NASDAQ: OSIP) plans move its U.S. operationds to a 43-acre campus it bought in N.Y., for $27 the company announced. “We have recognized that we will only trul y capture the full strategic value of our oncology franchiss if we simplify our business by bringinf together all the elements ofour U.S. operations onto a singlw site,” said Colin Goddard, CEO of OSI, in pres s release. The property it bought also will provide OSI spacse forfuture expansion. The company told the Boulder Camerqa newspaper earlier this year that it employeds 145 people inthe city.
OSI acquired its Boulder site in 2001 when it boughtfthe Boulder-based oncology unit of Gileard Sciences, formerly NeXstar Pharmaceuticals. OSI’s main drug is the cancer treatment Tarceva, whic h accounted for more than 80 percent ofthe company’ws $379.4 million in 2008 In addition to oncology, the company also researchex diabetes and obesity therapies in England. Consolidating OSI sites in New York, New Jerseu and Boulder at the Ardsley location is projectecd to save thecompany $15 million The moves will affect an estimated 350 U.S. the company said.
The company will receive New York economic incentivea because it decided to remain inthe state, OSI said in a pressx release.